Home Tags Labetuzumab govitecan

Tag: Labetuzumab govitecan

Phase II Results with Labetuzumab Govitecan (IMMU-130) Demonstrate Promissing Efficacy as...

Labetuzumab govitecan (IMMU-130), and investigational antibody-drug conjugate being developed by Immunogen, the second agent from the company's first-in-class antibody-drug conjugate (ADC) program, produced encouraging...

United States Patent and Trademark Office Awards New Patents to Immunomedics

Earlier this month the United States Patent and Trademark Office awarded U.S. Patent 9,458,242 to Immunomedics for additional claims under the patent family “Dosages of...

Immunomedics Receives U.S. patent for Labetuzumab Govitecan

Earlier this week Immunomedics announced the issuance of U.S. patent no. 9,226,973 for additional claims. Under the patent family “Dosages of immunoconjugates of antibodies and...

Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

An interim analysis of a mid-stage clinical study showed that labetuzumab govitecan, also known as  (IMMU-130), a novel antibody-drug conjugates or ADC being developed by...

FEATURED RESOURCES